Australia Adult Vaccines Market Overview, 2031

Australia Adult Vaccines Market is expanding steadily, supported by strong government immunization policies, rising health awareness, and technological innovation, positioning it as a key player within the Asia-Pacific vaccine industry. The market performance has been robust, where the adult vaccines contribute significantly to this growth, driven by an aging population, rising prevalence of infectious diseases, and preventive healthcare initiatives. The purpose and benefits of adult vaccines include reducing disease burden, lowering healthcare costs, and protecting vulnerable populations against influenza, pneumococcal disease, HPV, hepatitis, and COVID-19. Historically, Australia’s vaccine industry evolved from reliance on imported products to a strong domestic manufacturing and distribution base, supported by public-private R&D collaborations. The scope of products now spans subunit, mRNA, inactivated, live attenuated and viral vector vaccines. The scope of technology includes advanced cold-chain logistics, AI-driven clinical trials, and digital immunization records. Market components comprise manufacturers, distributors, healthcare providers, and government agencies. Key policies include the National Immunisation Program (NIP), which provides free vaccines for adults at risk, and the Pharmaceutical Benefits Scheme (PBS), which subsidizes essential vaccines. These policies ensure accessibility and high coverage rates. Challenges include vaccine hesitancy, high R&D costs, and logistical issues in rural areas. However, cultural trends show increasing acceptance of preventive healthcare, with customer behaviour leaning toward trust in government-backed programs and demand for innovative vaccines. The market connects with the parent global vaccine industry, contributing to worldwide immunization efforts. Compared to the Asia-Pacific market, Australia is smaller in scale but stronger in policy-driven coverage and premium healthcare infrastructure, whereas countries like India and China dominate in volume and manufacturing capacity.

According to the research report, "Australia Adult Vaccines Overview, 2031," published by Bonafide Research, the Australia Adult Vaccines is anticipated to grow at more than 7.25% CAGR from 2026 to 2031.The Australia Adult Vaccines Market is characterized by a competitive landscape shaped by global pharmaceutical giants and strong local players, supported by government-backed immunization programs and rising consumer awareness. The competitive landscape includes multinational firms such as Pfizer, Moderna, GlaxoSmithKline (GSK), and Sanofi, alongside local contributors like CSL Limited (Seqirus), which plays a pivotal role in vaccine manufacturing and distribution within Australia. Local players focus on influenza, pneumococcal, and shingles vaccines, while global firms dominate in newer technologies such as mRNA-based COVID-19 vaccines. Their products and services span preventive vaccines for influenza, HPV, hepatitis, shingles, and COVID-19, with unique selling propositions (USPs) centered on safety, efficacy, and innovation. CSL Seqirus, for example, emphasizes its seasonal flu vaccines tailored to the Southern Hemisphere, while Pfizer and Moderna highlight their cutting-edge mRNA platforms. Business models vary global firms rely on direct partnerships with governments and healthcare providers, while local companies balance domestic production, exports, and public-private collaborations. Pricing ranges from AUD 20–40 for seasonal flu shots to AUD 150–200 for specialized vaccines like shingles or HPV, which reflects a differentiation between mass immunization and premium preventive care. Market trends include growing demand for booster doses, combination vaccines, and eco-friendly packaging, alongside digital health integration for vaccine tracking. Opportunities lie in expanding adult immunization coverage, particularly among aging populations and rural communities, and in leveraging AI-driven R&D for faster vaccine development. Recent developments highlight Australia’s proactive stance where CSL Seqirus expanded its influenza vaccine production capacity, while Pfizer and Moderna continue to collaborate with the government on COVID-19 booster campaigns. Policy support through the National Immunisation Program (NIP) ensures accessibility, reinforcing Australia’s reputation as a leader in preventive healthcare.

The Australian Adult Vaccines Market, segmented by type into monovalent conjugate vaccines and multivalent conjugate vaccines, reflects a structured approach to disease prevention, balancing targeted protection with broader immunization strategies. Monovalent conjugate vaccines are designed to protect against a single pathogen or strain, offering highly specific immunity. In Australia, these vaccines are commonly used for diseases such as hepatitis B and certain meningococcal strains. Their strength lies in precision, ensuring strong immune responses against targeted infections. Monovalent vaccines are often deployed in high-risk groups or during outbreaks, where focused protection is critical. They are generally priced lower than multivalent options, making them accessible for widespread use under government programs like the National Immunisation Program (NIP). Multivalent conjugate vaccines, on the other hand, combine protection against multiple strains or pathogens within a single dose. Examples include pneumococcal and meningococcal vaccines, which cover several serotypes simultaneously. These vaccines are particularly valuable in adult populations, where comorbidities and age-related vulnerabilities increase the need for comprehensive protection. Though more expensive often ranging from AUD 100–200 per dose multivalent vaccines reduce the number of injections required, improving compliance and convenience. Market trends show growing demand for multivalent vaccines, driven by efficiency, broader coverage, and rising awareness of preventive healthcare. Opportunities lie in expanding adult immunization programs for aging populations, where multivalent vaccines can significantly reduce hospitalizations and healthcare costs. Challenges include vaccine hesitancy and the higher cost of advanced formulations, though government subsidies under the Pharmaceutical Benefits Scheme (PBS) help mitigate these barriers. Moreover, Australia balances cost-effective monovalent solutions with advanced multivalent vaccines, ensuring both targeted and comprehensive protection.

The Australian Adult Vaccines Market can also be segmented by disease categories such as varicella, human papilloma virus (HPV), measles, mumps & rubella (MMR), pneumococcal disease, and others, which reflects a comprehensive immunization framework designed to protect adults against both common and high-risk infections. The varicella vaccine is primarily targeted at adults who missed childhood immunization, offering protection against chickenpox and reducing complications such as shingles later in life. The HPV vaccine is a cornerstone of Australia’s preventive healthcare, widely administered to reduce cervical and other cancers, with strong uptake among young adults and women. The MMR vaccine continues to play a critical role in maintaining herd immunity, especially for adults in high-risk professions or those traveling internationally. Australia’s strong public health campaigns ensure high coverage, minimizing outbreaks of these highly contagious diseases. The pneumococcal vaccine is particularly important for older adults and those with chronic conditions, protecting against pneumonia, meningitis, and bloodstream infections. With Australia’s aging population, demand for pneumococcal vaccines is rising, supported by government subsidies under the National Immunisation Program (NIP). The others category includes vaccines for hepatitis A and B, influenza, and shingles, which collectively contribute to reducing hospitalizations and healthcare costs. Seasonal influenza vaccines, in particular, are widely adopted, with CSL Seqirus playing a major role in domestic production tailored to the Southern Hemisphere. Australia’s balanced approach includes targeting both preventable childhood diseases that persist into adulthood as well as age-related infections that pose significant risks. Cultural trends show strong public trust in vaccination programs, while government policies ensure accessibility.

Considered in this report
•Historic Year: 2020
•Base Year: 2025
•Estimated Year: 2026
•Forecast Year: 2031



Aspects covered in this report
• Australia Adult Vaccine Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top-profiled companies
• Strategic recommendation

By Types
• Monovalent Conjugate Vaccines
• Multivalent Conjugate Vaccines

By Disease
• Varicella
• Human Papilloma Virus
• Measles
• Mumps & Rubella
• Pneumococcal Disease
• Others